Loading
A Seattle safety trial of killer T cells grown to recognise cancer-testis proteins, which melanomas can carry but most normal adult tissues do not. It ran from 2002 to 2005.
The registry describes a phase I safety study of autologous CD8+ antigen-specific T-cell clones targeting cancer-testis antigens in metastatic melanoma, started in October 2002 and completed in June 2005; no enrolment figure is given (ClinicalTrials.gov NCT00045149). Cassian Yee is listed as study chair, the sponsor is Fred Hutchinson Cancer Center with the National Cancer Institute as collaborator, and the interventions are aldesleukin and therapeutic T cells (ClinicalTrials.gov NCT00045149). No results are posted.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, National Cancer Institute (NIH).
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/